Photys therapeutics announces research collaboration with novo nordisk to develop induced proximity phics technology for cardiometabolic diseases

Partnership leverages proprietary phics™ technology to bring together a kinase and target of interest to modulate protein function, in this case an undisclosed cardiometabolic target total potential deal value up to $186m in upfront, development and commercial milestone payments, in addition to r&d funding and tiered royalty payments on commercial sales waltham, mass., dec. 18, 2024 (globe newswire) -- photys therapeutics, inc., a proximity-based therapeutics company, today announced a multi-year collaboration and license agreement with novo nordisk to develop novel proximity-based therapeutics for a cardiometabolic disease target.
NVO Ratings Summary
NVO Quant Ranking